Age: 29.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Staphylococcal infection, Vaccination site swelling
Clinical narrative: PFIZER: Dose: 01 on 04Nov2021; Dose: 02 on 26Nov2021; Off Label Use; Booster; interchange of vaccine products; staphylococcus Aureus; Bumps around injection area, and face that itch; face that itch; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 29 year-old male patient received bnt162b2 (BNT162B2), administered in arm right, administration date 04Nov2021 (Lot number: FF2593) at the age of 29 years as dose 3 (booster), single and administered in arm right, administration date 26Nov2021 (Lot number: FH8027) as dose 4, single for covid-19 immunisation. Relevant medical history included: "Allergy" (unspecified if ongoing), notes: Past drug event:, drug name: No, reaction: allergy. The patient's concomitant medications were not reported. Vaccination history included: Moderna (Dose Number:01, Manufacturer: Moderna, Batch/Lot#: unknown, Route: unknown MD, Anatomical site of injection: Left& Right arm, No. of previous doses : 2), administration date: 05May2019, when the patient was 27 years old, for Immunization; Janssen covid-19 vaccine (Dose 2, Manufacturer: Janssen, Batch/Lot#: 043A21A, Anatomical site of injection: Left arm, No. of previous doses : 1), administration date: 15Jul2021, when the patient was 29 years old, for Covid-19 Immunization. The following information was reported: STAPHYLOCOCCAL INFECTION (medically significant) with onset 2021, outcome "unknown", described as "staphylococcus Aureus"; IMMUNISATION (medically significant) with onset 04Nov2021, outcome "unknown", described as "Booster"; OFF LABEL USE (medically significant) with onset 04Nov2021, outcome "unknown", described as "Off Label Use"; INTERCHANGE OF VACCINE PRODUCTS (medically significant) with onset 04Nov2021, outcome "unknown", described as "interchange of vaccine products"; VACCINATION SITE SWELLING (non-serious) with onset 2021, outcome "recovered with sequelae", described as "Bumps around injection area, and face that itch"; PRURITUS (non-serious) with onset 2021, outcome "recovered with sequelae", described as "face that itch"; INCORRECT DOSE ADMINISTERED (non-serious) with onset 26Nov2021, outcome "unknown", described as "PFIZER: Dose: 01 on 04Nov2021; Dose: 02 on 26Nov2021". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (04Nov2021) negative, notes: Nasal Swab. Therapeutic measures were taken as a result of staphylococcal infection. Therapeutic measures were not taken as a result of vaccination site swelling, pruritus.  Clinical Information: No hospitalization Prolonged Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient has been tested for COVID-19. Spoke with primary care doctor specifically about COVID and staphylococcus Aurous, on my annual visit I told her my symptoms and I was prescribed Amoxicillin -Pot clavulanate 825/125 mg tab. Also Ventolin HFA  108 MCG/ACT aerosol solution. Also recommendation for medical marijuana when affordable.  Follow-up attempts are completed. No further information is expected.